ArticleDisease markers2019
Association between the -844 G>A, HindIII C>G, and 4G/5G
Emmanuel Valdés-Alvarado, Miguel Huerta, Xochil Trujillo, Yeminia Valle, Jorge Ramón Padilla Gutiérrez, Mario Alberto Mireles-Ramírez, Miguel Angel Macías-Islas, Baltazar-Rodríguez Luz Margarita, José Francisco Muñoz-Valle
Open access · hybridAbstract read
In one paragraphArticle in Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors at 3 institutions in 1 country.
Emmanuel Valdés-AlvaradoInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco 44340, Mexico.ORCID https://orcid.org/0000-0001-6810-9203 Miguel HuertaCentro Universitario de Investigación Biomédica, Universidad de Colima, Colima, Colima 28040, Mexico.
Yeminia ValleInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco 44340, Mexico.ORCID https://orcid.org/0000-0002-4940-022X Jorge Ramón Padilla GutiérrezInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco 44340, Mexico.ORCID https://orcid.org/0000-0002-0240-2797 Mario Alberto Mireles-RamírezUnidad Médica de Alta Especialidad (UMAE), Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco 4430, Mexico.
Miguel Angel Macías-IslasDoctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco 44340, Mexico.
Baltazar-Rodríguez Luz MargaritaCentro Universitario de Investigación Biomédica, Universidad de Colima, Colima, Colima 28040, Mexico.
José Francisco Muñoz-ValleInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco 44340, Mexico.ORCID https://orcid.org/0000-0002-2272-9260 Universidad de Guadalajara · MXUniversidad de Colima · MXHospital de Especialidades · MX
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
introductionMultiple sclerosis is an inflammatory disease, where fibrin deposition and the impairment in its degradation have been shown to play an important role in the demyelination process. Tissue plasminogen activator (tPA) is a serine protease that enhances the conversion of plasminogen into its active form plasmin, the principal tPA inhibitor is the PAI-1. Several MATERIAL AND
methodsThe study group included 400 Mexican mestizo subjects: 200 unrelated patients and 200 unrelated individuals identified as control subjects. The analysis of
resultsA significant association was found between the CG genotype of the
Indexed as
Genetic Predisposition to DiseasePolymorphism, GeneticAdultDisease ProgressionFemaleGenotypeHumansInflammationMaleMexicoMultiple SclerosisOdds RatioPlasminogen Activator Inhibitor 1Polymerase Chain ReactionPolymorphism, Restriction Fragment LengthSex FactorsPlasminogen Activator Inhibitor 1PLAT protein, humanSERPINE1 protein, humanTissue Plasminogen Activator
Identifiers
PMID31687051
PMCPMC6800907
OpenAlexW2979367597
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390